Promiliad Biopharma is a privately funded company that was incorporated in 2002 to take advantage of drug discovery opportunities at the interface of synthetic chemistry and natural product fermentation.

Our efforts are focused on the discovery and development of novel small molecule therapeutics that address commercially important medical needs. Research is currently conducted in Montana (Missoula) and Ohio (Athens).

Currently drug discovery programs are targeted against pathogenic organisms including antibiotic resistant Gram negative bacteria, antifungal agents and the protozoal pathogen Cryptosporidium (causative agent of diarrheal disease in humans).

Promiliad has been successful in securing federal funding for its discovery programs, through the SBIR/STTR program.